Biocancell applies for FDA trial for pancreatic cancer drug

The company also plans to apply for a trial of its drug for ovarian cancer.

Biocancell Therapeutics Ltd. (TASE:BICL) has filed an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for a human Phase I/IIa clinical trial for the company's BC-819 pancreatic cancer treatment.

The trial will include six to nine patients at four medical centers in Israel and the US. Each patient will receive BC-819 twice a week for two weeks to test the drug's safety and effectiveness. The Virginia Biosciences Development Center and Israel-United States Binational Industrial Research and Development Foundation (BIRD-F) will jointly fund the $950,000 trial.

Biocancell also plans to file IND applications for a human Phase I/IIa clinical trial of BC-819 for the treatment of ovarian cancer.

Published by Globes [online], Israel business news - - on December 9, 2008

© Copyright of Globes Publisher Itonut (1983) Ltd. 2008

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018